IMMUNITYBIO, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
IMMUNITYBIO, INC. (IBRX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $9.46 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-04
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9.46M.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10.50M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10.86M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $11.72M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount as first filed |
|---|---|---|
| 2026-06-30 | $9.46M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $10.50M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $10.86M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $11.72M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $12.82M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $12.12M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $13.19M 10-K · filed 2025-03-03 | |
| 2024-09-30 | $14.30M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $14.79M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $15.92M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $17.09M 10-K · filed 2024-03-19 | |
| 2023-09-30 | $16.95M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $19.40M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $20.68M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $22.00M 10-K · filed 2023-03-01 | |
| 2022-09-30 | $23.36M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $24.77M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $19.76M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $20.60M 10-K · filed 2022-03-01 | |
| 2021-09-30 | $19.51M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $12.56M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $4.80M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $4.18M 8-K/A · filed 2021-04-22 | $2.21M 10-K · filed 2021-03-04 |
| 2020-09-30 | $2.55M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $2.40M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $2.67M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $2.96M 10-K · filed 2020-03-25 | |
| 2019-09-30 | $3.27M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $3.50M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $3.83M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |